This study found that 49% of female breast cancer patients treated with CDK4/6 inhibitors for at least three months developed alopecia, which significantly impacted their quality of life, with greater alopecia severity leading to worse emotional and functional well-being.
1 citations
,
January 2012 in “Türk jinekoloji ve obstetrik derneði dergisi/Türk Jinekoloji ve Obstetrik Derneği dergisi” This study observed that over 90% of patients undergoing paclitaxel and platinum chemotherapy for certain gynecological cancers experienced significant, yet reversible, alopecia by the end of treatment.
This study found that combining PRP with microneedling was more effective than PRP alone in improving hair growth and patient perception of hair loss in androgenetic alopecia up to Hamilton-Norwood grade 4.
28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” This study found that CDK4/6 inhibitors in hormone-positive metastatic breast cancer were linked to increased risks of fatigue, alopecia, and stomatitis compared to placebo.
June 2023 in “Journal of Cosmetic Dermatology” This study found that FUE megasession with a specific surgical design is an effective and satisfactory treatment for Asian patients with high-grade male androgenetic alopecia, achieving natural hair density and high patient and doctor satisfaction, with minimal side effects.